Empirical Anticoagulation Choice for Splanchnic Vein Thrombosis

Treatment Algorithm Based on Clinical Presentation

• For symptomatic splanchnic vein thrombosis, the American College of Chest Physicians recommends anticoagulation as a strong recommendation with moderate-certainty evidence 4
• The American College of Chest Physicians suggests no anticoagulation over anticoagulation for incidentally detected splanchnic vein thrombosis as a weak recommendation with low-certainty evidence 4

Initial Anticoagulation Choice

• Low molecular weight heparin at therapeutic doses should be initiated as first-line therapy for symptomatic splanchnic vein thrombosis 1, 2

Transition to Long-term Anticoagulation

• For short-term treatment in patients with active cancer, direct oral anticoagulants such as apixaban, edoxaban, or rivaroxaban are suggested over low molecular weight heparin 1
• For patients without cirrhosis, options include continuing low molecular weight heparin, transitioning to vitamin K antagonists, or direct oral anticoagulants 2

Duration of Anticoagulation

• A minimum duration of 3 months of anticoagulation is recommended for symptomatic splanchnic vein thrombosis 4, 2, 3
• In the absence of randomized trial data, it is common practice to treat splenic vein thrombosis for 6 months 1
• For patients with cancer and central venous catheter-related thrombosis that is not removed, anticoagulation should be continued as long as the catheter remains in place 4

Special Considerations

Monitoring During Treatment

• Perform cross-sectional imaging every 3 months to assess response to treatment 2
• Recanalization can be expected to occur up to 6 months after starting treatment 2
• Monitor anti-Xa activity in overweight patients, pregnant patients, and those with poor kidney function receiving low molecular weight heparin 2

Risk Assessment Before Initiating Anticoagulation

• Screen for gastrointestinal varices before initiating anticoagulation as they are predictors of bleeding risk 2, 3
• Assess for signs of intestinal infarction which requires urgent surgical intervention 2

Management of Complications

• For chronic splenic vein thrombosis with signs of portal hypertension, consider beta blockers, variceal banding or sclerosis 2
• In cases of intestinal infarction, immediate surgical evaluation is required to resect necrotic sections of the bowel 2
• For patients with progressive thrombosis not responding to anticoagulation, consider transjugular intrahepatic portosystemic shunt 1, 2

Limitations of Current Evidence

• There is inadequate evidence available to determine the optimum management of visceral/splanchnic vein thrombosis, particularly regarding the need for therapeutic anticoagulation 5
• The conditional recommendation for short-term treatment with anticoagulants or observation is due to the unknown balance of effects between treatment and observation in the context of very-low-certainty evidence 5